A shorter pill schedule for advanced colon cancer worked as well, with fewer side effects
In the PRABITAS trial in Japan, published Oct. 24, 2026, in The Lancet, a 14-day schedule of trifluridine-tipiracil plus bevacizumab was as good for survival as the standard 28-day one, with far…